Oman International Pharmaceutical Congress Kicks Off
The Oman International Pharmaceutical Congress (OIPCX2026) commenced this evening at the Oman Convention and Exhibition Center, proudly carrying the theme “Excellence for the Patient”. Under the auspices of His Excellency Dr. Hilal bin Ali Al-Sabti, the Minister of Health, the event, which attracts about 1,500 participants from the healthcare sector and pharmaceutical experts from 13 nations, is set to unfold over three days.
This congress positions the journey of medication from the laboratory to the patient at the heart of Gulf and international scientific discussions, featuring participation from five global health organizations and around 65 exhibitors.
Key Discussions and Themes
Raed bin Mahmoud Al-Sabri, the General Director of Medical Supply at the Ministry of Health and President of the Congress, emphasized the importance of viewing the congress’s theme from a strategic perspective, asserting that the patient is not merely the final word in the sentence but the first and most significant. He highlighted that excellence serves as a means, partnership as a path, and the patient as the ultimate goal.
According to officials, the congress will explore two critical drug journeys: the first encompasses research, manufacturing, quality control, and supply up to reaching the patient, while the second begins upon reaching the patient, involving transformation of knowledge into therapeutic decisions that impact lives.
Gene Therapies in Focus
The discussions will cover gene therapies, cell treatments, and precision medicine, which redefine the boundaries of what is possible. These therapies demand rigorous pharmaceutical care and oversight to ensure their quality and safety. Additionally, an efficient supply chain is necessary to guarantee timely availability despite potential disruptions, as emphasized by Al-Sabri.
Furthermore, topics such as genetic pharmacy, biopharmaceuticals, CAR-T therapies, and artificial intelligence’s role in shaping the future of pharmacy will be central to the agenda. The congress will also address how to optimize pharmaceutical practice to align with the health priorities of the Gulf Cooperation Council (GCC) states.
A Comprehensive Scientific Program
The scientific program of the congress covers the entire medication journey, starting from genetics and clinical trials through to dispensing, safety, and health economics. The opening day featured workshops focused on regulatory submissions, enhancing medication use among the elderly, and the importance of safety in transitions between care settings.
The second day will tackle the role of genetic pharmacy in clinical practice, discussing a lipid-lowering treatment tailored for the Omani population, and will include sessions on patient-centered systems to ensure safer healthcare practices.
Addressing Medication Errors
Medication errors present significant costs that are often preventable. As stated by Professor Ahmad bin Hamdan Al-Jadiah, President of the Saudi Association of Clinical Pharmacy, most errors occur at the delivery points among stakeholders. To address these points of failure, he proposed four foundational strategies, including shared data systems for patient records and a unified product safety identity.
Education and training of healthcare professionals are crucial, as is the need for shared accountability with unified governance and performance indicators. Al-Jadiah pointed out that the Gulf States have a unique opportunity to align visions and funding for improvement in pharmaceutical practices.
Building Partnerships for Sustainable Health
The congress aims to enhance integration across pharmaceutical sectors by uniting practice, education, research, and regulatory bodies. This alignment is crucial, as challenges in the medication journey often arise at handover points. The platform also facilitates scientific exchange and international collaboration among experts, particularly from GCC nations.
Through these efforts, the congress promotes patient-centered pharmaceutical care and optimal medication use while fostering pharmaceutical safety initiatives. Innovation and digital transformation will be explored, with an emphasis on evidence-based practices and the integration of health technology assessment in clinical guidelines in collaboration with the British National Institute for Health and Care Excellence (NICE).
Future Directions in Pharmaceutical Care
Looking ahead, the congress aims to not only provide recommendations but also develop strategies for a more resilient pharmaceutical supply chain. This will include policy papers supported by a commitment to economic evaluations and health technology assessments. As the congress unfolds, stakeholders will be encouraged to foster ongoing dialogues around patient care, safety, and the implications of technology in health services.
As the event concludes, it is evident that the insights gathered will significantly influence Oman’s pharmaceutical landscape, reinforcing its ambition to be a regional hub in the pharmaceutical industry while aligning with the goals set forth in Vision Oman 2040.

